Fusion polypeptides comprising mucin-domain polypeptide linkers
View Patent ↗The invention provides fusion proteins having improved bioactivity comprising a first polypeptide fusion partner and a second polypeptide fusion partner wherein the first fusion partner is linked to the second fusion partner by a mucin-domain polypeptide linker and wherein the bioactivity of the fusion protein of the invention is improved as compared to fusion of the first polypeptide fusion partner and the second polypeptide fusion partner in the absence of the mucin-domain polypeptide linker. Mucin-domain polypeptide linkers comprise a mucin domain that is rich in potential glycosylation sites, and has a high content of serine and/or threonine and proline, which can represent greater than 40% of the amino acids within the mucin domain and further comprise at least about 60% of its mass due to the glycans.
1. A fusion protein having improved bioactivity comprising a first polypeptide fusion partner and a second polypeptide fusion partner wherein the first fusion partner is linked to the second fusion partner by a mucin-domain polypeptide linker, wherein the first fusion partner is: sTNFR2, CTLA4, TACI, LFA, IL-1RI, IL-1RAcP, VEGF receptor, TPO receptor agonists, EPO receptor agonists, GLP-1, or exendin-4, and wherein the second fusion polypeptide comprises all or a portion of an immunoglobulin comprising an Fc region, and wherein the mucin domain polypeptide linker comprises at least one domain of tandem repeat comprising SEQ ID NO: 14 and wherein the improved bioactivity of the fusion protein is increased half-life, and wherein the half-life of the fusion protein is improved as compared to fusion of the first polypeptide fusion partner and the second polypeptide fusion partner in the absence of the mucin-domain polypeptide linker.
2. The fusion protein of claim 1 , wherein the mucin-domain polypeptide linker comprises between 1 and 5 tandem repeats.
3. The fusion protein of claim 1 , comprising a mucin-domain polypeptide linker of 10-100 total residues.
4. A composition comprising the fusion protein of claim 1 and at least one pharmaceutically acceptable carrier.
5. A fusion protein of claim 1 wherein the first fusion partner is IL1-Ra.
6. The fusion protein of claim 5 having the amino acid sequence of SEQ ID NO: 2.